FDA, 23andMe Open Up Market Pathway For DTC Genetics
This article was originally published in The Gray Sheet
Executive Summary
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
You may also be interested in...
23andMe Opens Up FDA Pathway For DTC Genetic Predisposition Tests
23andMe has made it full circle with at least 10 direct-to-consumer genetic predisposition tests gaining FDA go-ahead for testing services to provide information on an individual's risk for developing Alzheimer's, Parkinson's, and celiac disease, among others. The de novo classification comes three-and-half years after the firm's DTC genetic testing service was forced off the market by FDA, and two years after it was able to relaunch carrier-screening test services.
Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.
Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.